CD22 and lymphoma: In patients treated with an agent targeting CD22, CD24 may serve to identify normal and neoplastic B cells; however, not all cases of B-lymphoblastic leukemia/lymphoma are CD24 positive, so analysis for additional B cell markers, such as CD79a, may be helpful [18,19].